Francis Medical Announces Close of Record $80 Million Series C Equity Financing

Funding will continue supporting VAPOR 2 pivotal clinical study and U.S. commercialization of Vanquish Water Vapor Ablation proprietary prostate cancer treatment

MINNEAPOLIS, January 7, 2025 / - Francis Medical, Inc., a privately-held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney and bladder cancer, today announced the completion of the company's oversubscribed $80 million Series C equity financing, the largest fundraising round to date for the company.

Read more.